close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apimeds Pharmaceuticals US, Inc. Common Stock (NY:APUS)

1.620 +0.160 (+10.96%)
Official Closing Price Updated: 8:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Apimeds Pharmaceuticals US, Inc. Common Stock

News headline image
Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
News headline image
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
From Apimeds Pharmaceuticals US, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today